← Back to patent-cliff list
Naloxone intranasal (Amphastar)
Tier C — Watch / tradeNaloxone intranasal (Amphastar)
Amphastar Pharmaceuticals Inc
Originator
2023
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Opioid receptors
Brand：Rextovy
Indications (approved)：药物过量
Regional status
US
Approved
2023-03-07
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Naloxone intranasal (Amphastar)?
Approved indications include: 药物过量.
When does the Naloxone intranasal (Amphastar) patent expire?
No public expiry year is available for Naloxone intranasal (Amphastar) yet; this page updates once verified.
How do I get a quote for Naloxone intranasal (Amphastar) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27